Cargando…

Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer

Detalles Bibliográficos
Autores principales:	Nakai, Hidekatsu, Matsumura, Noriomi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061489/ https://www.ncbi.nlm.nih.gov/pubmed/37007537 http://dx.doi.org/10.21037/atm-22-6389

Ejemplares similares

Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs
por: Nakai, Hidekatsu, et al.
Publicado: (2022)

Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)
por: Nakai, Hidekatsu, et al.
Publicado: (2023)

Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer
por: Takamatsu, Shiro, et al.
Publicado: (2023)

Endometriosis-Associated Ovarian Cancer: The Origin and Targeted Therapy
por: Murakami, Kosuke, et al.
Publicado: (2020)

Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer
por: Hamilton, Gerhard
Publicado: (2020)

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
por: Takaya, Hisamitsu, et al.
Publicado: (2020)

Recurrent colon perforation after discontinuation of bevacizumab for ovarian cancer
por: Nonaka, Michiko, et al.
Publicado: (2018)

Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial
por: Lyon, Kristopher A., et al.
Publicado: (2020)

First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
por: Marchetti, Claudia, et al.
Publicado: (2019)

Histopathological subtyping of high-grade serous ovarian cancer using whole slide imaging
por: Miyagawa, Chiho, et al.
Publicado: (2023)

REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Clinical Determinants Affecting Indications for Surgery and Chemotherapy in Recurrent Ovarian Granulosa Cell Tumor
por: Nakai, Hidekatsu, et al.
Publicado: (2019)

Treatment for Locally Resectable Stage IIIC1 Cervical Cancer: A Retrospective, Single-Institution Study
por: Kashima, Yoko, et al.
Publicado: (2023)

Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most?
por: Babaier, Abdulaziz, et al.
Publicado: (2023)

Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma
por: Murakami, Kosuke, et al.
Publicado: (2021)

Subtypes of Ovarian Cancer and Ovarian Cancer Screening
por: Koshiyama, Masafumi, et al.
Publicado: (2017)

First-line treatment of ovarian cancer: questions and controversies to address
por: Ledermann, Jonathan A.
Publicado: (2018)

Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Correction to: Quality of life after laparoscopic hysterectomy versus abdominal hysterectomy
por: Kotani, Yasushi, et al.
Publicado: (2021)

Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort
por: Conic, Irena, et al.
Publicado: (2022)

Research Article Quality of life after laparoscopic hysterectomy versus abdominal hysterectomy
por: Kotani, Yasushi, et al.
Publicado: (2021)

A case report of bladder and intestinal endometriosis, and the relationship between sex hormone receptor expression and PIK3CA mutation analysis
por: Kanto, Akiko, et al.
Publicado: (2021)

Measures for Safe Laparoscopic Sacrocolpopexy: Preoperative Contrast-Enhanced Computed Tomography and Perioperative Ultrasonography
por: Kotani, Yasushi, et al.
Publicado: (2021)

Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma
por: Tate, Shinichi, et al.
Publicado: (2021)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

First-line chemotherapy for ovarian cancer – the controversy continues
por: Kaye, S B
Publicado: (2002)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis
por: Neyt, Mattias, et al.
Publicado: (2018)

Clinical Efficacy of Ovarian Cancer Screening
por: Koshiyama, Masafumi, et al.
Publicado: (2016)

Bevacizumab in the treatment of ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2011)

Adult granulosa cell tumors of the ovary: a retrospective study of 30 cases with respect to the expression of steroid synthesis enzymes
por: Kitamura, Sachiko, et al.
Publicado: (2017)

New first-line treatment strategies for advanced lung squamous cell carcinoma
por: Cai, Xiuyu, et al.
Publicado: (2020)

Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation
por: Zhuang, Hongqing, et al.
Publicado: (2016)

Progression of choroidal metastasis of ovarian serous cystoadenocarcinoma after intravitreal bevacizumab treatment
por: Kuo, Irene C., et al.
Publicado: (2013)

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
por: Chen, Hao, et al.
Publicado: (2023)

Combination of immunotherapy with chemotherapy in first line treatment of metastatic gastric cancer? Too much, too little or just right?
por: Ng, Matthew C. H., et al.
Publicado: (2020)

Recurrence of uterine myoma after myomectomy: Open myomectomy versus laparoscopic myomectomy
por: Kotani, Yasushi, et al.
Publicado: (2017)

Superparamagnetic iron oxide as a tracer for sentinel lymph node detection in uterine cancer: a pilot study
por: Murakami, Kosuke, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients
por: Berton, Dominique, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f68la94jooj1fvpl59du3et147